[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy-induced-neutropenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy-induced-neutropenia":150},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,84,109,136,163,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100587312","phase-2-telpegfilgrastim-vs-filgrastim-for-secondary-prevention-of-chemotherapy-induced-neutropenia-in-pediatric-solid-tumors-100587312",false,"NCT06926751","Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors","A Multicenter, Randomized, Controlled Study of Telpegfilgrastim Versus Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Children and Adolescents With Solid Tumors Receiving High-Intensity Chemotherapy Regimens","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed malignant solid tumor requiring high-intensity chemotherapy, with ≥2 remaining chemotherapy cycles, and either:\n\n   * Previous febrile neutropenia(FN) or dose-limiting neutropenia in the prior chemotherapy cycle without prophylactic granulocyte colony-stimulating factor (G-CSF);\n   * Previous FN or dose-limiting neutropenia in the prior chemotherapy cycle despite prophylactic G-CSF.\n2. Age ≥6 to ≤24 years.\n3. Eastern Cooperative Oncology Group Performance Status ≤1.\n4. Normal bone marrow hematopoietic function: hemoglobin ≥75 g\u002FL, white blood cell count ≥3.0×10\\^9\u002FL, platelets ≥80×10\\^9\u002FL, and neutrophils ≥1.5×10\\^9\u002FL.\n5. Anticipated survival ≥8 months.\n6. Willing to participate, with written informed consent signed by the patient or legal guardian.\n\nExclusion Criteria:\n\n1. Bone marrow involvement at screening.\n2. Uncontrolled localized or systemic infection.\n3. Known hypersensitivity to Telpegfilgrastim, recombinant human granulocyte-colony stimulating factor(rhG-CSF), or other pegylated recombinant human granulocyte colony stimulating factor(PEG-rhG-CSF) agents.\n4. Concurrent participation in any other investigational drug or device trial.\n5. Severe organ dysfunction: total bilirubin, alanine aminotransferase(ALT), or aspartate transaminase(AST) \\>2.5 × upper limit of normal(ULN) (or \\>5 × ULN in patients with liver metastases), serum creatinine \\>5 × ULN.\n6. Severe psychiatric disorders affecting informed consent provision or adverse event assessment.\n7. Any condition deemed by the investigator to compromise patient safety or interfere with study outcomes, including risks from the investigational product or confounding adverse event evaluation.","ALL","6 Years","24 Years",{"count":20,"type":21},132,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to evaluate the efficacy and safety of Telpegfilgrastim (a PEGylated recombinant human granulocyte colony-stimulating factor, PEG-rhG-CSF) compared to Filgrastim (short-acting rhG-CSF) in preventing chemotherapy-induced neutropenia (CIN) in children and adolescents aged 6-24 years with malignant solid tumors receiving high-intensity chemotherapy regimens. The main questions it aims to answer are:\n\n* Does Tuopefilgrastim reduce the incidence of febrile neutropenia (FN) in the first chemotherapy cycle (Cx+1) compared to Filgrastim?\n* How do the two treatments compare in terms of duration and severity of neutropenia, chemotherapy delays\u002Fdose reductions, antibiotic use, and bone pain incidence? Researchers will compare the Telpegfilgrastim group (3:1 ratio, 99 participants) with the Filgrastim group (33 participants) to determine if Telpegfilgrastim demonstrates superior efficacy and safety.\n\nParticipants will:\n\n* Receive subcutaneous injections of either Telpegfilgrastim (33 μg\u002Fkg, single dose) or Filgrastim (5 μg\u002Fkg\u002Fday, multiple doses) 24 hours after each chemotherapy cycle.\n* Undergo blood tests, physical exams, and temperature monitoring during follow-up visits.\n* Be assessed for bone pain severity using age-appropriate scales (FLACC or Wong-Baker).\n* Complete two chemotherapy cycles with close safety and efficacy monitoring.",[27,28,29,30],"Solid Tumors","Children","Adolescent","Chemotherapy Induced Neutropenia","RECRUITING","2026-05-06",{"date":34,"type":35},"2026-05-07","ACTUAL",{"date":37,"type":35},"2025-06-12",{"date":39,"type":21},"2027-09-01",{"name":41,"class":42},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":63,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100578269","home-monitoring-of-complete-blood-count-performed-by-patients---a-pilot-study-on-the-implementation-process-in-south-baltic-countries-100578269","NCT06809101","Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.","AMBeR eBlood","Inclusion Criteria:\n\n* legally competent patients\n* aged 18 or older\n* diagnosed with cancer (ICD-10: C00\\* - C97\\*)\n* enrolled at the Department of Oncology\u002FHematology for outpatients\n* participants who are willing and able to give informed consent for participation in the study\n* participants should receive chemotherapy in Daily Chemotherapy Unit and be within 4 weeks of chemotherapy initiation, and the expected duration of chemotherapy should be at least 12 weeks from inclusion\n\nExclusion Criteria:\n\n* inability to give informed consent due to mental capacity or language barrier\n* patient unable or unlikely to be able to perform fine manipulation required to use lancet or cartridge to obtain capillary blood sample and result\n* known bleeding disorder\n* bad circulation preventing the patient from getting enough blood drops to perform the test","18 Years",{"count":53,"type":21},265,"OBSERVATIONAL","Introduction:\n\nThe number of diagnosed cancers is systematically increasing every year. Cancer patients need to undergo regular blood tests to monitor safety and eligibility for treatment. In case of poor blood results, the chemotherapy session must be omitted. For patients living far from the center, this means unnecessary travel with involvement of helpers, additional costs, increased potential of hospital acquired infections, and frustration associated with missed opportunity for treatment.\n\nAims:\n\nThe primary aim of this study is to gain knowledge about successful implementation of remote, home monitoring of complete blood count to cancer patients during and after systemic treatment for cancer. The secondary aim of the AMBeR collective study protocol is to pilot new technology, gain more context around future investigations and verify costs and changes in patient treatment pathways.\n\nMethodology:\n\nThe investigators will test implementation of home blood monitoring in three South Baltic Countries (DK, PL, GER). Each site will participate in the implementation study with study group á n=33 (total n=165) and control group n=20 (total n=100). The duration of the study is planned for 4 cycles of chemotherapy for each patient and a 3-month follow up period. The first cycle of learning and training at the Outpatient Daily Clinic, then the remaining 3 cycles of blood monitoring at home. The average cycle length is 21-30 days, number of measurements will be determined individually depending on the diagnosis. At a baseline, after 4 cycles of chemotherapy (12-16 weeks) and after a 3-month follow-up period, parallel studies will be carried out in both the study and control groups, using mixed methods the investigators will assess outcomes of reach, effectiveness, adoption, implementation and maintenance (RE-AIM).\n\nExpected benefits:\n\nImplementation of the AMBeR study should reduce the amount of unnecessary and nontherapeutic hospital visits and improve manageability and independence of the patients. The investigators believe that the decrease in the number of hospital visits will diminish the risk of infection for vulnerable individuals, as well as save costs for patients and hospitals. These factors will also translate into better logistics of chemotherapy units, decreased carbon-dioxide trail, and improved quality of life and patient empowerment.",[57,58,59,60,61,62],"Cancer","Cancer-related Problem\u002FCondition","Chemotherapy","Chemotherapy-induced Neutropenia","Chemotherapy Induced Anaemia","Chemotherapy Induced Thrombocytopenia",[64,65,66,67,68,69,70,71,72,73],"home blood monitoring","complete blood count","cancer","chemotherapy","implementation","research","e-health","oncology","home-based","feasibility","2026-02-26",{"date":76,"type":35},"2026-02-27",{"date":78,"type":35},"2025-03-17",{"date":80,"type":21},"2027-03-31",{"name":82,"class":42},"Pomeranian Medical University Szczecin",5,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":108},"100600360","telpegfilgrastim-injection-to-reduce-the-risk-of-neutropenia-in-patients-with-solid-tumor-100600360","NCT07096479","Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor","A Real World Study on the Efficacy and Safety of Telpegfilgrastim Injection for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Solid Tumor","Inclusion Criteria:\n\n1. Male or female, age ranging from 18 to 70 years old (excluding 70 years old);\n2. body weight ≥45 kg;\n3. Histologically or cytologically confirmed diagnosis of malignant solid tumor;\n4. Solid tumor patients who receive a 3-week chemotherapy regimen have been evaluated as high-risk for FN or evaluated as having moderate risk for FN, but with an increased risk factor for neutropenia associated with the chemotherapy regimen;(The risk assessment of FN in tumor chemotherapy is based on \" Chinese Society of Clinical Oncology (CSCO) guidelines for standardized management of tumor chemoradiotherapy related neutropenia(2021 edition)\" and \" Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China(2023 edition)\";\n5. Karnofsky Performance Scale(KPS) score≥70;\n6. The total number of white blood cells and absolute value of neutrophils before chemotherapy should not be lower than normal values: WBC ≥ 3.5 × 109\u002FL, ANC ≥ 1.5 × 109\u002FL;\n7. Subject has a life Expectation of at least 6 month；\n8. Subjects voluntarily and strictly comply with the research protocol requirements and sign a written informed consent for.\n\nExclusion Criteria:\n\n1. Received any other PEG-rhG-CSF within 4 weeks prior to participating in this study;\n2. Patients receiving intermittent or continuous chemotherapy regimens such as albumin paclitaxel and capecitabine;\n3. Previously or expected to receive extensive radiation therapy (\\>25% of total bone marrow);\n4. Individuals with significant functional impairments in important organs such as the heart, lungs, liver, and kidneys:\n\n   Liver function indicators (ALT, TBil)\\>2.5 ULN; Tumor patients with liver metastasis have liver function indicators (ALT,TBil)\\>5ULN; Hepatitis B virus infection, hepatitis C virus infection, or cirrhosis; Renal function Cr\\>1.5ULN;\n5. Pregnant or breastfeeding woman ;\n6. hypersensitive to rhG-CSF or other biological agents;\n7. Investigators judged other situations that may affect the progress and results of clinical research.","70 Years",{"count":93,"type":21},318,"The objective of this real world study is to confirm the efficacy and saftey of Telpegfilgrastim injection for the prevention of chemotherapy-induced Neutropenia in Patients With Malignant solid tumor.",[60],[97],"Drug Therapy","2025-07-24",{"date":100,"type":35},"2025-07-31",{"date":102,"type":35},"2024-08-15",{"date":104,"type":21},"2025-08-15",{"name":106,"class":107},"Anhui Provincial Hospital","OTHER_GOV",2,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":43},"100557408","breath-analysis-for-the-detection-of-invasive-fungal-infections-100557408","NCT06537726","Breath Analysis for the Detection of Invasive Fungal Infections","Real-time Breath Analysis for the Detection of Invasive Fungal Infections in Neutropenic High-risk Patients","REDEFINE","Inclusion Criteria:\n\n* Diagnosis of acute leukemia\n* Planned chemotherapy with a duration of hospitalisation of 2 weeks or longer\n* Neutropenia (\\\u003C500\u002Fµl) present at inclusion or planned chemotherapy with expected neutropenia (\\\u003C500\u002Fµl) for more than 7 days\n\nExclusion Criteria:\n\n* Unable to follow instructions for breath analysis\n* Anatomic abnormalities precluding the use of a mouthpiece for breath analysis",{"count":118,"type":21},130,"Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality. As these patients typically have severe thrombocytopenia, direct diagnostic sampling with invasive procedures is often not possible due to the high peri-interventional risk. Therefore, the presumptive diagnosis of IFI is primarily based on compatible lung findings on computed tomography and serologic detection of fungal cell wall components, which, however, have limited sensitivity and specificity.\n\nWith the present study, the investigators aim to determine a set of specific volatile biomarkers in leukemia patients with proven or probable IFI using secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS).",[121,122,123,124,60,125,126],"Leukemia","Leukemia, Myeloid","Leukemia, Lymphoblastic","Neutropenia","Invasive Fungal Infections","Invasive Pulmonary Aspergillosis","2025-04-09",{"date":129,"type":35},"2025-04-10",{"date":131,"type":35},"2024-08-19",{"date":133,"type":21},"2027-10-31",{"name":135,"class":42},"University of Zurich",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":144,"maxAge":51,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":43},"100581975","phase-2-clinical-study-on-the-safety-efficacy-and-pharmacokinetics-of-telpegfilgrastim-in-pediatric-cancer-patients-with-chemotherapy-100581975","NCT06857292","Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy","Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim Injection in Pediatric Cancer Patients with Chemotherapy","Telpegfilgrast","Inclusion Criteria:\n\n* Patients with 14≤ age \\\u003C 18 years;\n\n  * Newly diagnosed patients with non-myeloid malignancies who are confirmed by histopathology or cytology to require intensive chemotherapy (first course of chemotherapy or second course of chemotherapy);\n\n    * Primary prevention (G-CSF 24 to 72 hours after the first use of chemotherapy agents with myelosuppression to prevent the occurrence of febrile neutropenia (FN)) or secondary prevention (if FN or dose-restricted neutropenia occurred in a patient during a previous chemotherapy cycle) is required. Prophylactic use of G-CSF can be considered for the next chemotherapy cycle.\n\nFebrile neutropenia (FN) : Oral temperature \\>38.3 ° C (axillary temperature \\>38.1 ° C) or oral temperature \\>38.0 ° C (axillary temperature \\>37.8 ° C) with ANC\\\u003C0.5×10\\^9\u002FL for 2 consecutive measurements within 2 hours, or ANC is expected to decrease to \\\u003C0.5×10\\^9\u002FL within 48 hours.\n\n* KPS score ≥50 or Lansky (LPS) score ≥50;\n\n  * Normal hematopoietic function of bone marrow (ANC≥1.5×10\\^9\u002FL, PLT≥80×10\\^9 \u002FL, Hb≥75g\u002FL, WBC≥3.0×10\\^9\u002FL, and not exceeding the upper limit of normal value);\n\n    * Life expectancy of at least 6 months; ⑦ Obtain written informed consent.\n\nExclusion Criteria:\n\n* Received any rhG-CSF within 3 weeks prior to study participation;\n\n  * Received any antibody coupling drug (ADC) drugs with potential blood toxicity within 3 weeks before participating in the study;\n\n    * Recipients of hematopoietic stem cell transplantation or organ transplantation;\n\n      * Clinical trials of other drugs were being conducted within 2 months before enrollment;\n\n        * There is no control of infection, body temperature ≥38℃; ⑥ Liver function test: total bilirubin (TBIL) alanine aminotransferase (ALT.) and aspartate aminotransferase (AST.) were more than 2.5 times the upper limit of normal value; ⑦ Renal function test: serum creatinine (Cr.) \\> 1.5 times the upper limit of normal value; ⑧Other conditions considered by the researchers to be contraindications for this study.","14 Years",{"count":146,"type":21},97,[24],"This study is a multicenter, single-arm, prospective study. The study population includes children with cancer who require high-intensity chemotherapy. The study aims to evaluate the safety and effectiveness of Telpegfilgrastim in preventing neutropenia in children with cancer (neuroblastoma, sarcoma, lymphoma, etc.) undergoing chemotherapy, while also studying the pharmacokinetic characteristics of Telpegfilgrastim in children with cancer.",[150],"Chemotherapy-Induced Neutropenia",[152,153],"Telpegfilgrastim","pediatric cancer","2025-02-26",{"date":156,"type":35},"2025-03-04",{"date":158,"type":35},"2024-12-01",{"date":160,"type":21},"2025-12",{"name":162,"class":42},"Sun Yat-sen University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":183,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":43},"100565997","a-multi-cohort-study-of-efbemalenograstim-alfa-injection-for-preventing-anc-reduction-in-solid-tumor-patients-post-immune-chemotherapy-100565997","NCT06649448","A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.","A Multi-cohort, Open-label, Multi-center Exploratory Study of Efbemalenograstim Alfa Injection for Preventing Absolute Neutrophil Count (ANC) Reduction in Solid Tumor Patients Undergoing Immune-chemotherapy Regimen.","EF-001","Inclusion Criteria:\n\n* Patients voluntarily participate in this study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-ups;\n* Aged 18 years or older, regardless of gender;\n* Patients with histologically or cytologically confirmed stage IV small cell lung cancer (SCLC) (as per the 8th edition of the American Joint Committee on Cancer (AJCC)) or T3-4 SCLC with multiple pulmonary nodules or tumors\u002Fnodules too large to be included in a tolerable radiotherapy plan, stage IV non-small cell lung cancer (NSCLC) (as per the 8th edition of the International Association for the Study of Lung Cancer (IASLC) Thoracic Oncology Staging Manual), or stage IV esophageal squamous cell carcinoma (excluding adenosquamous carcinoma) who are not eligible for radical therapy;\n* Patients who have not previously received systemic anti-tumor therapy for advanced\u002Fmetastatic disease. For patients who have received neoadjuvant\u002Fadjuvant and radical concurrent chemoradiotherapy, screening is allowed if the time from the last chemotherapy to recurrence or progression exceeds 6 months. For patients who have received radiotherapy alone, screening is allowed after disease progression;\n* Patients planned to receive immunotherapy combined with at least 2 cycles of chemotherapy regimens with a high risk of severe neutropenia complicated by febrile neutropenia (FN) or medium FN risk regimens combined with ≥ 1 patient-specific risk factor. According to the \\"Chinese Expert Consensus on Diagnosis and Treatment of Neutropenia Induced by Chemotherapy for Cancer (2023 Version)\\", patient-specific factors are also crucial in influencing the risk of FN. The patient factors that increase the risk of FN mainly include: (1) Age \\> 65 years and receiving full-dose chemotherapy; (2) Prior chemotherapy or radiotherapy; (3) Persistent neutropenia (\\>10 days); (4) Bone marrow invasion by tumor; (5) Recent surgery and\u002For open trauma; (6) Poor overall physical condition with comorbidities such as liver (serum bilirubin \\> 2 times the upper limit of normal (ULN)), kidney (creatinine clearance ≤ 50 ml\u002Fmin), heart, lung, endocrine, and other underlying diseases; (7) Poor nutritional status; (8) Chronic immunosuppression, such as human immunodeficiency virus infection, organ transplantation, and long-term immunosuppression after transplantation; (9) Advanced disease.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score: 0-1;\n* Adequate organ and bone marrow function:\n\n  1. Blood routine examination criteria (without blood transfusion or blood products and without using G-CSF or other hematopoietic stimulating factors within 14 days to correct):\n\n     Hemoglobin (HB) ≥ 80g\u002FL; Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL; Platelet count (PLT) ≥ 100×109\u002FL;\n  2. Biochemical examination criteria:\n\n     Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5´ ULN; if there is liver metastasis, then ALT and AST ≤ 5´ ULN; Serum creatinine ≤ 1.5´ ULN;\n  3. Left ventricular ejection fraction \\> 50%;\n* The investigator judges that the patient can tolerate the treatment with Abegrimacostat Alpha.\n\nExclusion Criteria:\n\n* Patients diagnosed with acute congestive heart failure, cardiomyopathy, or myocardial infarction through clinical examination, electrocardiogram, or other means;\n* Individuals with a history of rubber allergy;\n* Patients who have received radiotherapy for bone lesions (patients who have received radiotherapy for lesions other than bone lesions can be enrolled 4 weeks after treatment);\n* Patients who have undergone bone marrow transplantation or stem cell transplantation;\n* Pregnant or lactating women;\n* Patients with alcoholism or drug abuse that affects their compliance in participating in the study;\n* Known allergy to granulocyte colony-stimulating factors or excipients in the study drug;\n* Use of other investigational drugs within 1 month prior to enrollment in this study;\n* Received treatment with recombinant human granulocyte colony-stimulating factor within 6 weeks prior to enrollment;\n* Presence of other primary malignancies, with the following exceptions: 1) Malignancies in complete remission for at least 2 years prior to enrollment and requiring no additional treatment during the study; 2) Non-melanoma skin cancer or malignant lentigo maligna that has been adequately treated and shows no evidence of disease recurrence; 3) Carcinoma in situ that has been adequately treated and shows no evidence of disease recurrence;\n* The investigator believes that the patient has a disease or symptom that makes them unsuitable for participation in this study, or that the study drug may harm the patient\\'s health or affect the assessment of adverse events.",{"count":172,"type":21},200,[174],"NA","This study is a multi-cohort, open-label, multi-center exploratory clinical research designed to evaluate the efficacy and safety of Efbemalenograstim alfa Injection in preventing neutropenia (reduction in absolute neutrophil count, ANC) in solid tumor patients undergoing immune checkpoint inhibitor (ICI) combined chemotherapy. A total of 200 solid tumor patients who are scheduled to receive at least 2 cycles of ICI combined chemotherapy will be enrolled. The study is divided into three cohorts:\n\nCohort 1: Small cell lung cancer (SCLC) patients receiving ICI combined with chemotherapy (etoposide + carboplatin\u002Fcisplatin).\n\nCohort 2: Non-small cell lung cancer (NSCLC) patients receiving ICI combined with chemotherapy (platinum-based\u002Ftaxane, pemetrexed\u002Fplatinum).\n\nCohort 3: Esophageal squamous cell carcinoma (ESCC) patients receiving ICI combined with chemotherapy (TP, which stands for cisplatin + taxane).",[177,30,178],"Solid Tumor Cancer","G-CSF",[180,181,178,182],"ICI combined with chemotherapy","ANC","Solid Tumor","NOT_YET_RECRUITING","2024-10-17",{"date":186,"type":35},"2024-10-18",{"date":188,"type":21},"2024-10-10",{"date":190,"type":21},"2026-05-31",{"name":192,"class":42},"Shandong Cancer Hospital and Institute",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":201,"maxAge":4,"enrollmentInfo":202,"targetDuration":204,"studyType":54,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":43},"100458120","danish-elder-lymphoma-patient-hematopoietic-investigation-100458120","NCT05245487","Danish Elder Lymphoma Patient Hematopoietic Investigation","Chemotherapy-induced Genomic Damage in Elderly Patients With Lymphoma: Prevalence, Evolution, and Clinical Consequences","DELPHI","Inclusion Criteria:\n\n* Diagnosis of r\u002Fr B-cell Non-Hodgkin lymphoma\n* In need of systemic treatment with second (2.) or higher line of active therapy for lymphoma\n* 60 years of age or older (no age maximum)\n\nExclusion Criteria:\n\n* Unable to give written consent\n* Non-Danish citizens","60 Years",{"count":203,"type":21},300,"10 Years","Every year approximately 300 Danish patients die from lymphoma. The median age at diagnosis is 70 years. Lymphoma can be efficiently treated with chemotherapy, and potentially cured. However, sufficient treatment is often hampered by toxicity, especially in elderly patients. It is also well known that the main risk factor for dying of lymphoma is age. New biologically targeted therapies with fewer side effects are becoming available for lymphoma treatment, however it is currently difficult to delineate which patients benefit from chemotherapy and which should be treated with novel expensive therapies.\n\nRecently, it has been discovered that chemotherapy can provoke growth of patient blood cells with DNA mutations. This leads to increased rates of treatment side effects and excess mortality. These defects have so far only been examined in younger patients below 70 years of age, where they are found in roughly 10% of patients. It remains unknown to what extent elderly individuals are affected, but the investigators hypothesize that the proportion and negative effects are much larger.\n\nTherefore, the investigators propose to investigate the frequency and evolution of these DNA mutations during chemotherapy in a prospective study of patients, who are either above 60 years of age and previously treated with chemotherapy for lymphoma in a nation-wide collaboration.\n\nBy using blood samples, advanced genetic analyses and patient-reported questionnaires, the investigators will study\n\n* The prevalence of these mutations and their consequences for patient wellbeing, treatment side effects (such as anemia, infections etc.) and mortality\n* The kinetics of these mutations during and after treatment, and explore possible evolutionary patterns of the inferred damages The investigators expect to include 300 patients in the study and that the first results will be ready in a timeframe of 4 years. The investigators hope to obtain new insights in the risk factors for physiological and mental health in lymphoma patients and thereby pave the way for improvements in wellbeing and survival of this underserved population.",[207,60,208,209],"Lymphoma","Chemotherapy-Related Leukemia","Chemotherapeutic Toxicity","2023-12-18",{"date":212,"type":35},"2023-12-22",{"date":214,"type":35},"2022-01-01",{"date":216,"type":21},"2035-01-01",{"name":218,"class":42},"Rigshospitalet, Denmark"]